Welcome to LookChem.com Sign In|Join Free

CAS

  • or

125515-31-3

Post Buying Request

125515-31-3 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier
  • N-[1,2-Dihydro-1-[(2R,6S)-6-(hydroxymethyl)-4-(triphenylmethyl)-2-morpholinyl]-2-oxo-4-pyrimidinyl]benzamide

    Cas No: 125515-31-3

  • No Data

  • No Data

  • Metric Ton/Day

  • SAGECHEM LIMITED
  • Contact Supplier

125515-31-3 Usage

Description

N4-Benzoyl-7'-OH-N-trityl Morpholino cytosine is a nucleoside analog chemical compound featuring a cytosine base with a benzoyl group, a trityl group, and a morpholino ring attached to it. N4-Benzoyl-7'-OH-N-trityl Morpholino cytosine is known for its improved stability and binding affinity due to the modifications on the cytosine base, making it a valuable asset in the fields of nucleic acid therapeutics and antisense technology.

Uses

Used in Pharmaceutical Research and Development:
N4-Benzoyl-7'-OH-N-trityl Morpholino cytosine is utilized as a research tool for studying nucleic acid interactions and designing therapeutic agents targeting specific nucleic acid sequences. Its enhanced stability and binding affinity make it a promising candidate for the development of drugs that can modulate gene expression or interfere with nucleic acid functions.
Used in Drug Development:
In the field of drug development, N4-Benzoyl-7'-OH-N-trityl Morpholino cytosine is used as a potential therapeutic agent. The presence of the morpholino ring improves the solubility and bioavailability of the compound, which is crucial for its pharmaceutical applications and effectiveness in treating various diseases.
Used in Medicinal Chemistry:
N4-Benzoyl-7'-OH-N-trityl Morpholino cytosine is employed in medicinal chemistry for the synthesis of novel compounds with potential therapeutic properties. Its unique structure allows for the exploration of new chemical entities that can be tailored for specific medical applications, expanding the scope of available treatments.

Check Digit Verification of cas no

The CAS Registry Mumber 125515-31-3 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,5,5,1 and 5 respectively; the second part has 2 digits, 3 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 125515-31:
(8*1)+(7*2)+(6*5)+(5*5)+(4*1)+(3*5)+(2*3)+(1*1)=103
103 % 10 = 3
So 125515-31-3 is a valid CAS Registry Number.

125515-31-3Relevant articles and documents

Design, synthesis and molecular modeling study of conjugates of ADP and morpholino nucleosides as a novel class of inhibitors of PARP‐1, PARP‐2 and PARP‐3

Abramova, Tatyana V.,Belousova, Ekaterina A.,Eltsov, Ilia V.,Ivanisenko, Nikita V.,Ivanisenko, Vladimir A.,Kurgina, Tatjana A.,Kutuzov, Mikhail M.,Lavrik, Olga I.,Peshkov, Roman Y.,Sherstyuk, Yuliya V.,Silnikov, Vladimir N.,Sukhanova, Maria V.,Zakharenko, Alexandra L.

, (2020/01/28)

We report on the design, synthesis and molecular modeling study of conjugates of adenosine diphosphate (ADP) and morpholino nucleosides as potential selective inhibitors of poly(ADP‐ribose)polymerases‐1, 2 and 3. Sixteen dinucleoside pyrophosphates containing natural heterocyclic bases as well as 5‐haloganeted pyrimidines, and mimicking a main substrate of these enzymes, nicotinamide adenine dinucleotide (NAD+)‐molecule, have been synthesized in a high yield. Morpholino nucleosides have been tethered to the β‐phosphate of ADP via a phosphoester or phosphoramide bond. Screening of the inhibiting properties of these derivatives on the autopoly(ADP‐ribosyl)ation of PARP‐1 and PARP‐2 has shown that the effect depends upon the type of nucleobase as well as on the linkage between ADP and morpholino nucleoside. The 5‐ iodination of uracil and the introduction of the P–N bond in NAD+‐mimetics have shown to increase inhibition properties. Structural modeling suggested that the P–N bond can stabilize the pyrophosphate group in active conformation due to the formation of an intramolecular hydrogen bond. The most active NAD+ analog against PARP‐1 contained 5‐iodouracil 2?-aminomethylmorpholino nucleoside with IC50 126 ± 6 μM, while in the case of PARP‐2 it was adenine 2?‐aminomethylmorpholino nucleoside (IC50 63 ± 10 μM). In silico analysis revealed that thymine and uracil‐based NAD+ analogs were recognized as the NAD+‐analog that targets the nicotinamide binding site. On the contrary, the adenine 2?‐aminomethylmorpholino nucleoside-based NAD+ analogs were predicted to identify as PAR‐analogs that target the acceptor binding site of PARP‐2, representing a novel molecular mechanism for selective PARP inhibition. This discovery opens a new avenue for the rational design of PARP‐1/2 specific inhibitors.

Improved protocol for the synthesis of flexibly protected morpholino monomers from unprotected ribonucleosides

Pattanayak, Sankha,Paul, Sibasish,Nandi, Bappaditya,Sinha, Surajit

, p. 763 - 782 (2013/01/16)

An inexpensive and much improved protocol has been developed for the synthesis of protected morpholino monomers from unprotected ribonucleosides in high overall yield, using oxidative glycol cleavage and reductive amination strategy. Unlike the previous methods, the present strategy allows installing the exocyclic amine protections at a later stage, and thus avoids the use of expensive, or commercially unavailable, exocyclic amine-protected ribonucleosides as starting materials. To demonstrate the flexibility of the present method in choosing protecting groups, the monomers have been protected with several such groups of different deblocking properties at the exocyclic amine position.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 125515-31-3